These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21279548)

  • 1. Diagnosis and treatment of primary aldosteronism.
    Mulatero P; Monticone S; Veglio F
    Rev Endocr Metab Disord; 2011 Mar; 12(1):3-9. PubMed ID: 21279548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of primary aldosteronism.
    Mulatero P; Monticone S; Bertello C; Tizzani D; Iannaccone A; Crudo V; Veglio F
    Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):188-93. PubMed ID: 20389241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary aldosteronism: from bench to bedside.
    Sukor N
    Endocrine; 2012 Feb; 41(1):31-9. PubMed ID: 22042487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.
    Funder JW; Carey RM; Mantero F; Murad MH; Reincke M; Shibata H; Stowasser M; Young WF
    J Clin Endocrinol Metab; 2016 May; 101(5):1889-916. PubMed ID: 26934393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies.
    Marzano L; Colussi G; Sechi LA; Catena C
    Am J Hypertens; 2015 Mar; 28(3):312-8. PubMed ID: 25336498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism.
    Ahmed S; Hundemer GL
    Front Endocrinol (Lausanne); 2022; 13():861581. PubMed ID: 35557845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
    Satoh M; Maruhashi T; Yoshida Y; Shibata H
    Hypertens Res; 2019 Jun; 42(6):817-824. PubMed ID: 30948836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of primary aldosteronism: Clinical practice guidelines of the Taiwan Society of Aldosteronism.
    Tseng CS; Chan CK; Lee HY; Pan CT; Peng KY; Wang SM; Huang KH; Tsai YC; Wu VC; Chueh JS;
    J Formos Med Assoc; 2024 Mar; 123 Suppl 2():S125-S134. PubMed ID: 37328332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surgical treatment for primary aldosteronism].
    Luzuy-Guarnero V; Mehier P; Wuerzner G; Matter M; Zingg T
    Rev Med Suisse; 2024 Jun; 20(878):1163-1166. PubMed ID: 38867561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of primary aldosteronism: from screening to subtype differentiation.
    Mulatero P; Dluhy RG; Giacchetti G; Boscaro M; Veglio F; Stewart PM
    Trends Endocrinol Metab; 2005 Apr; 16(3):114-9. PubMed ID: 15808809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Primary Aldosteronism in Resistant Hypertension.
    Stavropoulos K; Imprialos KP; Patoulias D; Katsimardou A; Doumas M
    Curr Hypertens Rep; 2022 Aug; 24(8):285-294. PubMed ID: 35445928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MANAGEMENT OF ENDOCRINE DISEASE: Diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited.
    Williams TA; Reincke M
    Eur J Endocrinol; 2018 Jul; 179(1):R19-R29. PubMed ID: 29674485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
    Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension.
    Mulatero P; Sechi LA; Williams TA; Lenders JWM; Reincke M; Satoh F; Januszewicz A; Naruse M; Doumas M; Veglio F; Wu VC; Widimsky J
    J Hypertens; 2020 Oct; 38(10):1929-1936. PubMed ID: 32890265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-Dependent Risk of Atrial Fibrillation in Patients With Primary Aldosteronism After Medical or Surgical Treatment Initiation.
    Kim KJ; Hong N; Yu MH; Lee H; Lee S; Lim JS; Rhee Y
    Hypertension; 2021 Jun; 77(6):1964-1973. PubMed ID: 33866798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confirmatory tests in the diagnosis of primary aldosteronism.
    Mulatero P; Monticone S; Bertello C; Mengozzi G; Tizzani D; Iannaccone A; Veglio F
    Horm Metab Res; 2010 Jun; 42(6):406-10. PubMed ID: 20119882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term outcome of Aldosteronism after target treatments.
    Wu VC; Wang SM; Chang CH; Hu YH; Lin LY; Lin YH; Chueh SC; Chen L; Wu KD
    Sci Rep; 2016 Sep; 6():32103. PubMed ID: 27586402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and treatment of primary aldosteronism.
    Rossi GP
    Rev Endocr Metab Disord; 2011 Mar; 12(1):27-36. PubMed ID: 21369868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A short review of primary aldosteronism in a question and answer fashion.
    Farrugia FA; Zavras N; Martikos G; Tzanetis P; Charalampopoulos A; Misiakos EP; Sotiropoulos D; Koliakos N
    Endocr Regul; 2018 Jan; 52(1):27-40. PubMed ID: 29453922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.